19 May 2013
Keywords: novartis, reports, strong, ph, iii, results, spp100
Article | 30 January 2006
Swiss drug major Novartis has reported positive Phase III results on SPP100 (aliskiren, Rasilez), a hypertension drug co-developed with
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 January 2006
17 May 2013
© 2013 thepharmaletter.com